Novel Lipases of Microbial Origin for Superior Performance
Novel lipases of microbial origin selected and engineered for best performance. A EUCODIS Bioscience Case Study EUCODIS Bioscience offers a
Read moreNovel lipases of microbial origin selected and engineered for best performance. A EUCODIS Bioscience Case Study EUCODIS Bioscience offers a
Read moreArvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read moreReal-world data has shown the Vaxzevria vaccine (formerly AZD1222), co-developed by AstraZeneca, the University of Oxford and its spin-out company,
Read moreMerck, also known as MSD, revealed that the U.S. Food and Drug Administration (FDA) has authorised VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate
Read moreThe University of Oxford has commenced a Phase I clinical trial of a novel HIV vaccine candidate with vaccinations underway
Read moreThe main protease (Mpro) is a key enzyme of SARS-CoV-2 and is required for viral replication and transcription. A Biosynth
Read moreQIAGEN officially confirmed a global cooperation agreement with Sysmex Corporation for the development and commercialization of cancer companion diagnostics, leveraging
Read moreThe path for India’s first mRNA vaccine import has been cleared with Cipla winning approval to distribute Moderna’s COVID-19 vaccine.
Read moreThe range of clinical responses to SARS-CoV-2 infection is extremely broad, a factor making the disease particularly difficult to properly
Read moreNucleai and Merck KGaA will collaborate utilizing Nucleai’s AI-powered platform to develop pathology-based biomarkers as companion diagnostics. Nucleai, a precision
Read more